Trial Profile

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDRX-42 (Primary)
Indications Gastrointestinal stromal tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms StrateGIST 1
Sponsors IDRx

Most Recent Events

17 Jan 2025 Planned number of patients changed from 240 to 269.
14 Nov 2024 Results presented in an IDRx media release
14 Nov 2024 According to an IDRx media release, Second-line cohort in the Phase 1b portion of StrateGIST 1 nearly fully enrolled.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com